PPP2R5D Antibody

What is PPP2R5D and why is it significant in neurological research?

PPP2R5D (serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform) functions as a key regulatory subunit that modulates the substrate selectivity, catalytic activity, and subcellular localization of protein phosphatase 2A complexes . This protein is abundantly expressed in the brain and critically involved in modulating neuronal pathways and signaling . Its significance in neurological research has grown substantially since the discovery that missense mutations in the PPP2R5D gene are strongly linked to neurodevelopmental disorders, intellectual disability, and autism spectrum disorders, collectively known as Jordan's syndrome . These connections make PPP2R5D antibodies invaluable tools for investigating the molecular mechanisms underlying these conditions and potentially developing therapeutic interventions.

Which experimental applications are suitable for PPP2R5D antibodies?

PPP2R5D antibodies have been validated for multiple experimental applications, with varying degrees of effectiveness depending on the specific antibody clone and preparation. Based on standardized validation protocols, the primary applications include:

• Western blotting (WB): For quantitative protein expression analysis and molecular weight determination

• Immunoprecipitation (IP): For protein-protein interaction studies and isolation of PPP2R5D complexes

• Immunofluorescence (IF)/Immunocytochemistry (ICC): For subcellular localization studies

• Flow cytometry (intracellular): For quantitative single-cell analysis

• Immunohistochemistry-paraffin (IHC-P): For tissue expression studies

When selecting an application, researchers should consider that some antibodies perform better in specific applications. For example, the antibody characterized in the search results (ab188323) demonstrated particularly strong performance in Western blot at dilutions as high as 1:100,000, indicating excellent sensitivity for this application .

How should researchers select appropriate cell lines for PPP2R5D studies?

When selecting cell lines for PPP2R5D studies, researchers should consider endogenous expression levels and relevant tissue contexts. Based on standardized protocols:

• Consult transcriptomics databases like DepMap to identify cell lines with sufficient expression (recommended threshold: >2.5 log₂ TPM+1)

• Consider HAP1 cells, which express PPP2R5D at levels above the average range of cancer cells analyzed

• When possible, incorporate both wild-type and knockout cell lines for experimental validation (e.g., parental and PPP2R5D KO HAP1 cells from Horizon Discovery)

For neurological studies, neuronal cell lines or primary neurons may be more physiologically relevant, though expression levels should be verified before proceeding with experiments.

What knockout-based validation approaches ensure PPP2R5D antibody specificity?

Knockout-based validation represents the gold standard for antibody specificity assessment. A rigorous approach involves:

• Side-by-side comparison of wild-type and PPP2R5D knockout cells using standardized protocols

• Multi-application testing across Western blot, immunoprecipitation, and immunofluorescence platforms

• Quantitative analysis of signal intensity between WT and KO samples

For immunofluorescence validation specifically, implementing a mosaic strategy enhances reliability:

• Label wild-type and knockout cell lines with different fluorescent dyes

• Mix populations and process on the same slide

• Image cells in the same field of view to minimize staining, imaging, and analysis bias

• Perform quantitative analysis of immunofluorescence intensity across hundreds of cells for statistical validity

This approach directly addresses reproducibility challenges that have plagued antibody research, enabling confident identification of antibodies that specifically recognize endogenous PPP2R5D protein.

How do researchers optimize Western blot protocols for detecting different PPP2R5D isoforms?

PPP2R5D exists in multiple isoforms with predicted molecular weights of 58kDa, 66kDa, and 70kDa based on sequence analysis . To optimize Western blot protocols for accurate detection:

• Sample preparation:

  • Use appropriate lysis buffers containing phosphatase inhibitors to preserve the native phosphorylation state

  • Denature samples at 95°C for 5 minutes in reducing conditions

• Gel selection and separation:

  • Use 8-10% SDS-PAGE gels for optimal separation of these mid-range molecular weight isoforms

  • Run gels at lower voltage (80-100V) for improved resolution between closely migrating isoforms

• Transfer and detection considerations:

  • Optimize antibody dilution (ab188323 performed well at extremely high dilutions of 1:100,000)

  • Include positive controls with known expression of specific isoforms

  • Consider cell-type specificity (the 70kDa band was consistently observed across C6, HepG2, 293T, HeLa, and Jurkat cell lysates)

When analyzing results, researchers should note that observed molecular weights may differ slightly from predicted values due to post-translational modifications or splice variants.

What approaches help resolve non-specific binding issues with PPP2R5D antibodies?

Non-specific binding can confound experimental interpretation. To improve specificity:

• For Western blotting:

  • Increase blocking stringency (5% milk or BSA in TBST for 1-2 hours)

  • Optimize primary antibody dilution through titration experiments

  • Increase washing duration and volume (5 washes x 5 minutes with TBST)

  • Consider using knockout lysates as negative controls to identify non-specific bands

• For immunofluorescence:

  • Implement more stringent blocking (5% BSA, 5% normal goat serum in PBS with 0.1% Triton X-100)

  • Extend primary antibody incubation to overnight at 4°C

  • Use knockout cells as controls to establish background signal levels

  • Consider alternative fixation methods if background persists

• For immunoprecipitation:

  • Pre-clear lysates with protein A/G beads before adding antibody

  • Use knockout lysates as negative controls to identify non-specific pull-downs

  • Optimize antibody-to-lysate ratios (1:50 dilution was effective for ab188323)

These optimizations should be methodically tested and documented to establish reproducible protocols.

How can immunoprecipitation protocols be optimized for PPP2R5D protein complex studies?

Immunoprecipitation is valuable for studying PPP2R5D-containing protein complexes. To optimize this approach:

• Antibody selection considerations:

  • Not all antibodies that perform well in Western blot will be effective for immunoprecipitation

  • Test multiple antibodies using standardized protocols to identify optimal performers

  • Consider epitope location relative to known protein interaction domains

• Methodological optimizations:

  • Maintain native conditions if studying intact complexes (avoid harsh detergents)

  • Include phosphatase inhibitors to preserve physiological phosphorylation states

  • For ab188323, a 1:50 dilution was effective for immunoprecipitating PPP2R5D from 293T cell lysates

  • Use goat anti-rabbit IgG peroxidase-conjugated secondary antibody (1:1500) for detection

• Validation approaches:

  • Compare immunoprecipitated proteins from wild-type versus knockout cells

  • Confirm depletion of target protein in post-immunoprecipitation supernatants

  • Verify specificity by mass spectrometry analysis of immunoprecipitated complexes

These methodological considerations help ensure that observed protein interactions are genuine and not artifacts of experimental conditions.

How are PPP2R5D antibodies utilized to investigate mechanisms of neurodevelopmental disorders?

PPP2R5D mutations are associated with Jordan's syndrome, characterized by intellectual disabilities and autism spectrum disorders . Researchers can employ PPP2R5D antibodies to investigate underlying mechanisms through:

• Comparative protein localization studies:

  • Use immunofluorescence to compare subcellular localization of wild-type versus mutant PPP2R5D in neuronal models

  • Combine with confocal microscopy to achieve high-resolution spatial information

  • Implement co-localization studies with known interacting partners or subcellular markers

• Phosphorylation status analysis:

  • Employ immunoprecipitation to isolate PPP2R5D complexes

  • Use phospho-specific antibodies to analyze altered phosphorylation states of PP2A substrates

  • Compare phosphatase activity between wild-type and mutant forms

• Protein-protein interaction studies:

  • Use proximity ligation assays in combination with PPP2R5D antibodies to visualize and quantify protein interactions in situ

  • Implement co-immunoprecipitation to identify altered binding partners in disease states

  • Combine with mass spectrometry for unbiased interaction profiling

These approaches provide mechanistic insights into how PPP2R5D mutations affect neuronal function, potentially revealing therapeutic targets for intervention.

What experimental strategies help assess PPP2R5D involvement in cell cycle regulation as it relates to neurodevelopmental pathology?

PPP2R5D's impact on cell cycle regulation in neuronal processes may provide insights into neurodevelopmental disorders . To investigate this connection:

• Temporal expression analysis:

  • Use Western blotting with optimized PPP2R5D antibodies to quantify expression across developmental stages

  • Implement cell synchronization protocols followed by immunoblotting to assess cell cycle-dependent expression

  • Combine with cell cycle markers for correlation analysis

• Subcellular dynamics studies:

  • Employ live-cell imaging with fluorescently tagged PPP2R5D to track localization during cell cycle progression

  • Use fixed-cell immunofluorescence at distinct cell cycle phases to create temporal snapshots

  • Implement super-resolution microscopy for detailed spatial information

• Functional studies in neuronal models:

  • Utilize shRNA or CRISPR techniques to create knockdown/knockout models

  • Rescue experiments with wild-type versus mutant PPP2R5D to assess functional consequences

  • Evaluate neuronal differentiation and maturation markers in relationship to PPP2R5D status

These methodological approaches help establish causative relationships between PPP2R5D dysfunction, cell cycle dysregulation, and neurodevelopmental pathology.

What criteria should guide selection among commercial PPP2R5D antibodies?

When selecting among multiple commercial PPP2R5D antibodies, researchers should consider:

• Validation evidence:

  • Prioritize antibodies validated using knockout controls

  • Review performance across multiple applications if multimodal experiments are planned

  • Assess validation in cells/tissues relevant to your experimental system

• Technical specifications:

  • Antibody type (monoclonal vs. polyclonal; recombinant vs. conventional)

  • Host species and isotype (to avoid cross-reactivity with other reagents)

  • Recognized epitope location and its conservation across species

• Application-specific performance:

  • Western blot: sensitivity (effective dilution) and specificity (single vs. multiple bands)

  • Immunofluorescence: signal-to-noise ratio and subcellular detail

  • Immunoprecipitation: efficiency of target enrichment

The systematic evaluation of six commercial PPP2R5D antibodies using standardized protocols provides a valuable resource for informed selection based on specific research needs .

How do experimental conditions influence antibody performance across different applications?

Antibody performance can vary significantly based on experimental conditions. Key considerations include:

• For Western blotting:

  • Sample preparation method (RIPA vs. milder lysis buffers)

  • Protein amount loaded (10-20μg typically used in validation studies)

  • Transfer method (wet vs. semi-dry)

  • Detection system (chemiluminescence vs. fluorescence-based)

• For immunofluorescence:

  • Fixation method (4% paraformaldehyde was used in validation studies)

  • Permeabilization agent (0.1% Triton X-100 was effective)

  • Blocking composition (BSA and normal goat serum combination reduced background)

  • Antibody incubation time (overnight at 4°C followed by 1-hour room temperature secondary incubation)

• For immunoprecipitation:

  • Lysis buffer composition

  • Antibody-to-lysate ratio

  • Incubation conditions

  • Washing stringency

These parameters should be systematically optimized for each antibody and experimental system, as performance can vary even among high-quality antibodies when conditions are altered.

How can researchers contribute to improved PPP2R5D antibody validation standards?

To advance PPP2R5D antibody validation standards, researchers should:

• Implement rigorous validation approaches:

  • Utilize knockout controls whenever possible

  • Perform multimodal validation across applications

  • Document detailed protocols and optimization parameters

• Practice open science principles:

  • Share detailed methodological information in publications

  • Contribute to community resources and databases

  • Provide feedback to commercial antibody manufacturers

• Address existing limitations:

  • Expand validation beyond cancer cell lines to include neuronal models

  • Evaluate antibody performance with PPP2R5D mutants relevant to neurodevelopmental disorders

  • Develop application-specific protocols optimized for different experimental contexts

By following these approaches, researchers can contribute to addressing antibody reproducibility challenges that have hampered scientific progress in the field .

What emerging techniques might enhance PPP2R5D research beyond traditional antibody applications?

While traditional antibody applications remain foundational, emerging techniques offer new opportunities for PPP2R5D research:

• Proximity-dependent labeling:

  • BioID or TurboID fusion proteins to identify proximal interactors in living cells

  • APEX2-based approaches for temporal interaction mapping

  • Combining with mass spectrometry for unbiased interaction profiling

• Advanced imaging approaches:

  • Super-resolution microscopy for detailed subcellular localization

  • Live-cell imaging with split fluorescent protein tags for dynamic interaction studies

  • Expansion microscopy for enhanced spatial resolution of protein complexes

• CRISPR-based genomic tagging:

  • Endogenous tagging of PPP2R5D to avoid overexpression artifacts

  • Inducible degradation systems for temporal control of protein levels

  • Allele-specific tagging to distinguish wild-type from mutant proteins